Key Takeaways
- 72% revenue growth, guidance reaffirmed: Consolidated revenue grew 72% YoY, and management remains confident of delivering 50% top-line growth and ~100% PAT growth for FY26.
- Margin dip is a timing story: EBITDA margin fell ~170 bps YoY to 24.8% as the new API unit incurred costs ahead of H2 revenue; sequential margin improved ~360 bps, and the annualised steady-state target of 25%-26% was reiterated.
- The US business is built for stability, not just growth: ~60%-70% of US revenue comes from government and controlled-substance contracts with 5-year fixed pricing, insulating the portfolio from the retail price erosion that hurts peers.
- The CDMO order book is firm but lumpy: A $23 million firm rolling-order book exists, but revenue conversion depends on regulatory approvals and partner tech transfers that take 8-15 months, making quarterly projections difficult.
- What to watch next quarter: Whether the acquired ANDA portfolio begins contributing revenue in H2 as guided, the pace of emerging-market margin expansion toward double digits, and any update on the US FDA inspection timeline for the Chhatral API facility.
Regulated Markets & the US Moat
- Government and controlled-substance dominance: ~60%-70% of the US business serves government agencies and controlled-substance markets, where national contracts are awarded for five years with one-to-two-year extensions, providing fixed pricing and predictable volumes that sharply reduce cash-flow volatility versus retail-exposed peers.
- Local manufacturing eliminates tariff risk: All formulation manufacturing is done in the US, with only very small API quantities procured from China and some from Europe, making the impact of any tariff escalation negligible.
- Capacity expansion underway: Two manufacturing lines are already operational; a third line is expected to come online in Q3 FY26 and a fourth by end of FY26, taking total capacity from 120 crore units to ~200 crore units. After that, the company plans to set up sterile manufacturing in the US.
- Acquired ANDA portfolio yet to contribute: ANDAs acquired from Dr. Reddy's, Breckenridge and Wockhardt contributed zero revenue in Q1 FY26; contribution is expected to begin in H2 FY26 with full impact visible from FY27.
- Steady-state growth expectation: On a going-forward basis, management assumes 20%-30% CAGR for the US regulated business.
Swapnil Shah: "Our entire formulation manufacturing is done locally in the US as we speak. In terms of APIs, we procure very small quantities from China and some quantities from Europe. In case of any escalation of tariffs for this region, the impact on our business would be negligible."
CDMO-CMO: The Emerging Second Engine
- Portfolio build-out accelerating: Five new products were added in Q1 FY26, taking the CDMO-CMO portfolio to ~27 products with over 50 in the pipeline. The firm order book stands at $23 million in rolling orders from partners, with additional discussions underway.
- Revenue conversion is slow by design: A product launched today takes 6-9 months to achieve meaningful sales because contracts must be signed, materialised, and supplies started. Development work takes 12-15 months before filing, and tech transfer plus new API source qualification takes 8-10 months for approval, sometimes 12 months or more.
- Top-five concentration: The top five products contribute 60%-70% of the entire CDMO business, a percentage not expected to change drastically as the segment ramps up. Management declined to name the products, citing NDAs with customers.
- Strategic split target: Management aims to keep own products and CDMO-CMO roughly equal on an annual basis, though the exact split is difficult to predict quarter-to-quarter because it depends on order inflow.
- Growth projection deferred: Management indicated 20%-30% CAGR going forward but said very accurate projections will only be possible by end of this calendar year or early next year, once visibility improves.
Swapnil Shah: "As we said, I think we would be able to guide 20%, 30% CAGR going forward. I think very accurate projections we'll be able to give by end of this year, early next year. I'm saying calendar year. That would be the right time for us to kind of give very accurate growth projections for the next year."
Emerging Markets: Volume-Led Turnaround
- Realisation improvement underway: Realisation moved from INR 1.2-1.3 per unit last year to ~INR 1.8 per unit today, driven by a shift toward more niche molecules and evolving go-to-market strategies. Revenue grew 32% YoY.
- Profitability still sub-scale: EBITDA margin was stagnant at ~6% in Q1, but management expects it to reach double digits this year and stabilise at 15%-17% on a sustainable annualised basis, with mid-teens targeted for next year. PAT is expected to be only marginally positive this year.
- The 719-product registration pipeline: All 719 products under registration are expected to be approved and launched within 18 months, with roughly 20% launching in each 3-6 month window. By that time, another 500-plus products will be under registration.
- Geographic mix is deliberately opaque: Management declined to break out country-wise revenue, stating that each quarter represents a different mix and such a breakdown would be misleading. Top markets include parts of Africa and Latin America, with Bolivia, Guatemala and Ecuador recently added.
India Branded Generics: Small Base, Fast Ramp
- Injectable segment nearly doubled: The monthly revenue run rate for injectables reached ~₹2.5 crores, with total branded generics revenue growing over 4x YoY to ₹8 crores in Q1.
- Pan-India ambition: The company currently has 80-85 field staff across ~22 states and is approved in top hospitals including Apollo, Sahyadri, AIIMS, PGI Chandigarh and HLL. Field force expansion is expected to deliver Pan-India presence by end of FY26.
- FY26 target: Revenue is expected to surpass ₹50 crores in FY26.
Margins, Cash Flow & Capex
- YoY margin decline explained: EBITDA margin fell ~170 bps YoY to 24.8%, driven entirely by increased employee costs and other expenses at the newly commissioned API unit, which will generate revenue only in H2. On a sequential basis, margin improved ~360 bps.
- Annualised steady-state target intact: Management expects the company to stabilise at a consolidated EBITDA margin of 25%-26% on an annualised basis.
- Operating cash flow turned positive: The company generated ~₹11 crores of positive operating cash flow in Q1 FY26, a milestone after periods of negative cash flow driven by continuous growth and reinvestment. Management is confident of sustained positive operating cash flow but asked investors to wait a couple of quarters before expecting clarity on the surplus percentage.
- Capex revised down: Full-year capex guidance was revised to INR 100-150 crores from INR 250 crores, with part of the spend spilling into next year.
- API facility timeline: The Chhatral API facility (capacity ~100-150 metric tons per year) is progressing as planned; a product DMF is being filed for an existing commercial product in the US as a second source, and management expects a US FDA inspection in Q2 FY27, with approval and inspection timelines described as very definite.
Sanjay Majmudar: "Negative cash flow is a function of continuous growth and reinvestment. I think it's a bit early for us to tell you that what percentage of the cash would be as a surplus positive cash. Let's wait for a couple of quarters. We have a lot of growth still coming, but we are very confident of continuous positive cash flow from the operations."
Portfolio Resilience & Risk Factors
- Low single-product dependency: Each product's revenue contribution is only 2%-2.5% of the consolidated total, so price erosion on any individual product has a protected, limited impact. Exposure to the retail channel, where price erosion is most acute, is deliberately limited.
- Own-product margins structurally higher: Own-product portfolios carry higher percentage margins than CDMO because they generate three distinct revenue streams: licensing fees, COGS, and profit share.
- Cough syrup exposure eliminated: The company does not manufacture any cough syrups; whatever registrations it previously held have been discontinued.
- No guidance-specific risks flagged: When asked about risk factors for achieving FY26 guidance, management stated it does not foresee anything over and above industry-level risk factors.
Swapnil Shah: "I don't foresee anything over and above what the industry risk factors are."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| FY26 revenue growth | 50% top-line growth over FY25 | FY26 full year |
| FY26 PAT growth | ~100% growth over FY25 | FY26 full year |
| H2 weighting | Second half bigger than first half across all business metrics | H2 FY26 |
| ANDA launches | ~15-16 ANDA products launched, majority in H2 | FY26 |
| Acquired ANDA revenue contribution | Revenue from Dr. Reddy's, Breckenridge, Wockhardt portfolios begins | H2 FY26, full impact FY27 |
| US manufacturing Line 3 | Operational | Q3 FY26 |
| US manufacturing Line 4 | Installed and operational | End of FY26 |
| US capacity | Expand from 120 crore units to ~200 crore units | By end of FY26 |
| Sterile manufacturing in US | Set up after four lines complete | After FY26 |
| API facility US FDA inspection | Inspection expected | Q2 FY27 |
| India branded generics revenue | Surpass ₹50 crores | FY26 |
| India branded generics presence | Pan-India field force coverage | End of FY26 |
| Emerging markets EBITDA | Double-digit | FY26 |
| Emerging markets EBITDA | Mid-teens, stabilising at 15%-17% annualised | FY27 / sustainable basis |
| Emerging markets PAT | Marginally positive | FY26 |
| Consolidated EBITDA margin | Stable at 25%-26% on annualised basis | Steady state |
| Capex | INR 100-150 crores (revised from INR 250 crores) | FY26 |
| Operating cash flow | Continuous positive cash flow from operations | Ongoing |
| Revenue mix | Regulated markets ~60%-70%, emerging markets ~30% | FY26 and FY27 |
| CDMO-CMO growth projection | 20%-30% CAGR | Going forward |
Key Metrics
| Metric | Q1 FY26 |
|---|---|
| Consolidated revenue | ₹138 cr, +72% YoY and +15% QoQ |
| EBITDA | ₹34 cr, +60% YoY |
| EBITDA margin | 24.8%, down ~170 bps YoY, up ~360 bps QoQ |
| PAT | ₹21 cr, +95% YoY |
| Operating cash flow | ~₹11 cr positive |
| Regulated markets revenue | ₹90 cr, +69% YoY and +40% QoQ |
| Regulated markets EBITDA margin | 35.5% |
| Emerging markets revenue | ₹29 cr, +32% YoY |
| Emerging markets EBITDA margin | 6% |
| Domestic branded generics revenue | ₹8 cr, >4x YoY |
| CDMO-CMO revenue | ~₹28 cr |
| CDMO-CMO order book | $23 million as of beginning of Q2 FY26 |
| USFDA-approved ANDAs | ~70 as of end of Q1 FY26 |
| Commercially launched ANDAs | 24 as of June 30, 2025 |
| FY26 ANDA launch plan | ~15–16 products, majority in H2 |
| Emerging markets product approvals | 308 as of June 30, 2025 |
| Emerging markets products under registration | 719 |
| Emerging markets realisation | ~₹1.8 per unit, up from ₹1.2–1.3 per unit last year |
| India branded generics monthly revenue run rate | ~₹2.5 cr, nearly doubled in recent months |
| FY26 revenue growth guidance | 50% over FY25 |
| FY26 PAT growth guidance | ~100% over FY25 |
| Annualised EBITDA margin target | 25%–26% |
| Emerging markets sustainable EBITDA margin target | 15%–17% |
| US manufacturing capacity expansion | 120 crore units to ~200 crore units, third line by Q3 FY26, fourth line by end of FY26 |
| Overall capex FY26 | ₹100–150 cr, revised from ₹250 cr earlier |
| Tax rate | ~20% on average |